DPP4 and diabetes mellitus: We found higher rates of second-generation diabetes drug use when the prescriber was an endocrinologist (SGLT-2 inhibitors: RR, 1.88 [95% CI, 1.46-2.42]; P < .001; DPP-4 inhibitors: RR, 1.44 [95% CI, 1.37-1.50]; P < .001; GLP-1 receptor agonists: RR, 2.35 [95% CI, 2.06-2.68]; P < .001) or when the prescribers’ panel had more than 50% of patients with diabetes (SGLT-2 inhibitors: RR, 1.75 [95% CI, 1.34-1.53]; P < .001; DPP-4 inhibitors: RR, 1.65 [95% CI, 1.58-1.72]; P < .001;GLP-1 receptor agonists: RR, 2.23 [95% CI, 1.91-2.60]; P < .001).